Market Cap 3.22B
Revenue (ttm) 263.50M
Net Income (ttm) -390.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -148.38%
Debt to Equity Ratio 0.00
Volume 10,497,101
Avg Vol 16,335,112
Day's Range N/A - N/A
Shares Out 452.97M
Stochastic %K 83%
Beta 0.71
Analysts Strong Sell
Price Target $8.85

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 260 7120
Address:
825 Industrial Road, Suite 100, San Carlos, United States
Hero2Zero
Hero2Zero Aug. 19 at 11:39 AM
$IOVA obviously biased to say merck/moderna news won’t significantly impact IOVA commercial success in the long run. Probably will see some short term price effect because this is IOVA and a strong fart will make it wilt for a bit. I would imagine it will have a more significant effect on replimmune since it highlights they can’t show systemic effect with a shot while Merck/moderna apparently can.
0 · Reply
Hero2Zero
Hero2Zero Aug. 19 at 11:34 AM
$IOVA just so you know, the charts predicted this Merck/Moderna news. *wink* *wink* *winkwinkwinkwinkwnkwnkwnknknknkkkkkk*
0 · Reply
Kingjake26
Kingjake26 Aug. 19 at 11:24 AM
$IOVA Not invested here but does the Merck news going to hurt this company?
2 · Reply
Always_neutral
Always_neutral Aug. 19 at 11:24 AM
$IOVA Merk and moderns cancer vaccine stopped after interim analysis, results not yet shared but stopping after first interim analysis is very positive. How that impacts IOVA: I believe they dealt with Stage III patients, not metastatic. Competition for sure but not entirely. We need iov-3001 regimen done ASAP. IMTX and OBX are also coming in 2028. Lungs is the key. Good luck. Oh! this might also eat REPL lunch and could be better used by the docs.
2 · Reply
onlyhereforiova
onlyhereforiova Aug. 19 at 11:23 AM
$IOVA all who wondering if Moderna vaccine affects IOVA? Rather not. Amtagvi's FDA label specifically requires unresectable or metastatic melanoma after prior PD-1 therapy. Moderna study is completely different.... these patients had their melanoma surgically removed, and Moderna/Merck vaccine is trying to stop it from recurring. Will it shrink the market? Maybeeeee a bit for melanoma, in the long run.. imagine 100 high risk patients who have melanoma removed. Without the vaccine: 100 patients → Keytruda → X% eventually recur → some become metastatic → some eventually reach Amtagvi With an effective vaccine: 100 patients → Keytruda + vaccine → fewer recur → fewer eventually become Amtagvi candidates So (MAYBE) a small effect in the long run.. for melanoma. Currently, in my opinion, IOVA is seen as an emerging TIL platform, with lung and many other potential areas in the pipeline. GO GO IOVA holders! HOLD
1 · Reply
Eugen337
Eugen337 Aug. 19 at 11:23 AM
$IOVA Just because.
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 19 at 11:18 AM
$IOVA I think MRNA/MRK melanoma news taking toll
0 · Reply
BigGainTom
BigGainTom Aug. 19 at 11:17 AM
$IOVA You really think RFK Jr is going to greenlight an mRNA vaccine?
0 · Reply
Gius_me
Gius_me Aug. 19 at 11:14 AM
$IOVA may Moderna news affect us?
1 · Reply
BigGainTom
BigGainTom Aug. 19 at 11:13 AM
$IOVA No one wants mRNA vaccines anymore... I can't image Moderna getting any leg here.
1 · Reply
Latest News on IOVA
Iovance Biotherapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2026


Iovance Biotherapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Iovance Biotherapeutics Earnings release: Q2 2026


Iovance Biotherapeutics Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Iovance Biotherapeutics Quarterly report: Q2 2026


Iovance Biotherapeutics reports Q2 EPS (11c), consensus (13c)

2026-08-06T12:05:43.000Z - 12 days ago

Iovance Biotherapeutics reports Q2 EPS (11c), consensus (13c)


Iovance Biotherapeutics Slides: Corporate presentation

Jun 30, 2026, 7:00 AM EDT - 7 weeks ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics files automatic mixed securities shelf

2026-06-18T20:35:12.000Z - 2 months ago

Iovance Biotherapeutics files automatic mixed securities shelf


Iovance Biotherapeutics Transcript: AGM 2026

Jun 10, 2026, 11:00 AM EDT - 2 months ago

Iovance Biotherapeutics Transcript: AGM 2026


Iovance Biotherapeutics to Present at Upcoming Conference

May 21, 2026, 8:05 AM EDT - 3 months ago

Iovance Biotherapeutics to Present at Upcoming Conference


Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

2026-05-07T13:16:25.000Z - 3 months ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)


Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026


Iovance Biotherapeutics Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Earnings release: Q1 2026


Iovance Biotherapeutics Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Iovance Biotherapeutics Quarterly report: Q1 2026


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing


Iovance Biotherapeutics to Present at Upcoming Conferences

Feb 26, 2026, 8:00 AM EST - 6 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences


Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025


Iovance Biotherapeutics Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Annual report: Q4 2025


Iovance Biotherapeutics Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Earnings release: Q4 2025


Iovance Biotherapeutics Slides: Corporate presentation

Feb 24, 2026, 7:00 AM EST - 6 months ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics Slides: Corporate presentation

Jan 9, 2026, 7:00 AM EST - 7 months ago

Iovance Biotherapeutics Slides: Corporate presentation


Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025


Iovance Biotherapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Quarterly report: Q3 2025


Iovance Biotherapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Earnings release: Q3 2025


Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025


Iovance Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Quarterly report: Q2 2025


Iovance Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings release: Q2 2025


Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.


Hero2Zero
Hero2Zero Aug. 19 at 11:39 AM
$IOVA obviously biased to say merck/moderna news won’t significantly impact IOVA commercial success in the long run. Probably will see some short term price effect because this is IOVA and a strong fart will make it wilt for a bit. I would imagine it will have a more significant effect on replimmune since it highlights they can’t show systemic effect with a shot while Merck/moderna apparently can.
0 · Reply
Hero2Zero
Hero2Zero Aug. 19 at 11:34 AM
$IOVA just so you know, the charts predicted this Merck/Moderna news. *wink* *wink* *winkwinkwinkwinkwnkwnkwnknknknkkkkkk*
0 · Reply
Kingjake26
Kingjake26 Aug. 19 at 11:24 AM
$IOVA Not invested here but does the Merck news going to hurt this company?
2 · Reply
Always_neutral
Always_neutral Aug. 19 at 11:24 AM
$IOVA Merk and moderns cancer vaccine stopped after interim analysis, results not yet shared but stopping after first interim analysis is very positive. How that impacts IOVA: I believe they dealt with Stage III patients, not metastatic. Competition for sure but not entirely. We need iov-3001 regimen done ASAP. IMTX and OBX are also coming in 2028. Lungs is the key. Good luck. Oh! this might also eat REPL lunch and could be better used by the docs.
2 · Reply
onlyhereforiova
onlyhereforiova Aug. 19 at 11:23 AM
$IOVA all who wondering if Moderna vaccine affects IOVA? Rather not. Amtagvi's FDA label specifically requires unresectable or metastatic melanoma after prior PD-1 therapy. Moderna study is completely different.... these patients had their melanoma surgically removed, and Moderna/Merck vaccine is trying to stop it from recurring. Will it shrink the market? Maybeeeee a bit for melanoma, in the long run.. imagine 100 high risk patients who have melanoma removed. Without the vaccine: 100 patients → Keytruda → X% eventually recur → some become metastatic → some eventually reach Amtagvi With an effective vaccine: 100 patients → Keytruda + vaccine → fewer recur → fewer eventually become Amtagvi candidates So (MAYBE) a small effect in the long run.. for melanoma. Currently, in my opinion, IOVA is seen as an emerging TIL platform, with lung and many other potential areas in the pipeline. GO GO IOVA holders! HOLD
1 · Reply
Eugen337
Eugen337 Aug. 19 at 11:23 AM
$IOVA Just because.
0 · Reply
beachsidefreddy
beachsidefreddy Aug. 19 at 11:18 AM
$IOVA I think MRNA/MRK melanoma news taking toll
0 · Reply
BigGainTom
BigGainTom Aug. 19 at 11:17 AM
$IOVA You really think RFK Jr is going to greenlight an mRNA vaccine?
0 · Reply
Gius_me
Gius_me Aug. 19 at 11:14 AM
$IOVA may Moderna news affect us?
1 · Reply
BigGainTom
BigGainTom Aug. 19 at 11:13 AM
$IOVA No one wants mRNA vaccines anymore... I can't image Moderna getting any leg here.
1 · Reply
neilc1920
neilc1920 Aug. 19 at 11:06 AM
$IOVA repl gets mention on cnbc, moderna gets mention on cnbc both for melanoma. Iova crickets
1 · Reply
parsnips
parsnips Aug. 19 at 11:03 AM
$IOVA xbi surging premarket....could be a fun day in bioland :)
0 · Reply
smolawoo
smolawoo Aug. 19 at 10:53 AM
$IOVA The race is heating up https://www.cnbc.com/2026/08/19/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html
1 · Reply
MS1974
MS1974 Aug. 19 at 10:26 AM
$IOVA 🌏
0 · Reply
tedevan
tedevan Aug. 19 at 10:21 AM
0 · Reply
Kai_01
Kai_01 Aug. 19 at 9:46 AM
$IOVA 'And a very close friend has just heard that her own trial treatment, TIL therapy, is working, giving her hope that would have been unimaginable only a few years ago, without these workers’ labour.'. Over 300 staff at the UK’s Institute of Cancer Research are on indefinite strike under the banner “First-class science, second-rate pay.” Beautiful to hear about another positive TIL story, but most importantly, raising awareness about the precarious situation of medical and research professionals worldwide. In Mallorca, doctors are sleeping in cars and vans because they can’t afford the rent. https://www.counterfire.org/article/first-class-science-second-rate-pay/
2 · Reply
drose0527
drose0527 Aug. 19 at 9:31 AM
$IOVA stocks like IOVA don’t continue to set 52 weeks highs every day. For the last 11 days we have push the 52 weeks high to 7.31. This is due for a correction!!! At this level. The previous 52 week high of 4.33 which was old resistance held for a full year ever since we flipped that IOVA has been making new highs the last 3 months. With a majority of it coming in the last 2 weeks. Sorry but stocks don’t continue to push higher like that especially in a rebuild phase like IoVA is in. market will move accordingly and it will not let moon shots go on IOVA. It has to prove it self at every opportunity to advance.
1 · Reply
AndreaLocke441
AndreaLocke441 Aug. 19 at 9:18 AM
$RZLV $IOVA $AAOI $MRVL RZLV remains highly speculative, Iovance advances cell therapies for cancer, Applied Optoelectronics benefits from data-center optical demand, and Marvell benefits from AI networking and custom silicon. I'm watching funding, clinical milestones, AI capex, optical demand, and semiconductor growth.
1 · Reply
Over80
Over80 Aug. 19 at 8:19 AM
$IOVA impressive... the stock shows a strong momentum. Hold and buy during dip!
0 · Reply
HenryTabisula478
HenryTabisula478 Aug. 19 at 7:13 AM
$UUP $USAR $IOVA $MSFT UUP provides U.S.-dollar exposure, USA Rare Earth remains tied to critical-mineral development, Iovance advances cell therapies for cancer, and Microsoft benefits from cloud and AI spending. I'm watching dollar strength, permitting, clinical milestones, Azure growth, and AI capex.
0 · Reply
wenmoon_stonks
wenmoon_stonks Aug. 19 at 7:13 AM
$IOVA don't bend but trend
0 · Reply
LeeLarue913
LeeLarue913 Aug. 19 at 7:04 AM
$RZLV $IOVA $AAOI $MRVL RZLV remains highly speculative, Iovance advances cell therapies for cancer, Applied Optoelectronics benefits from data-center optical demand, and Marvell benefits from AI networking and custom silicon. I'm watching funding, clinical milestones, AI capex, optical demand, and semiconductor growth.
0 · Reply